雪榕生物(300511) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit of between 29 million and 40 million CNY for the year 2025, a significant recovery from a loss of 617 million CNY in the same period last year[5]. - The net profit after deducting non-recurring gains and losses is projected to be between 5 million and 16 million CNY, compared to a loss of 634 million CNY in the previous year[5]. - The company anticipates a non-recurring gain of approximately 24 million CNY impacting net profit, primarily from government subsidies and asset disposal gains[8]. - The financial data provided is a preliminary estimate and will be finalized in the 2025 annual report, pending audit by the accounting firm[9]. Industry Outlook - The edible mushroom industry is expected to stabilize and recover in the second half of 2025, leading to an increase in product prices and improved gross margins[7]. Operational Improvements - The company achieved a breakthrough in the new strain of white enoki mushroom, significantly increasing production capacity utilization and reducing overall costs[8]. - The company has reduced period expenses by approximately 45 million CNY through strict cost control measures[8].